Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBITDA (2023 - 2025)

Historic EBITDA for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$51.1 million.

  • CG Oncology's EBITDA fell 8069.98% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.1 million, marking a year-over-year decrease of 8768.29%. This contributed to the annual value of -$114.7 million for FY2024, which is 10679.54% down from last year.
  • Latest data reveals that CG Oncology reported EBITDA of -$51.1 million as of Q3 2025, which was down 8069.98% from -$48.7 million recorded in Q2 2025.
  • CG Oncology's EBITDA's 5-year high stood at -$9.7 million during Q1 2023, with a 5-year trough of -$51.1 million in Q3 2025.
  • For the 3-year period, CG Oncology's EBITDA averaged around -$28.4 million, with its median value being -$25.9 million (2024).
  • As far as peak fluctuations go, CG Oncology's EBITDA tumbled by 13113.88% in 2024, and later plummeted by 8069.98% in 2025.
  • CG Oncology's EBITDA (Quarter) stood at -$19.4 million in 2023, then tumbled by 96.58% to -$38.0 million in 2024, then plummeted by 34.38% to -$51.1 million in 2025.
  • Its last three reported values are -$51.1 million in Q3 2025, -$48.7 million for Q2 2025, and -$42.2 million during Q1 2025.